Objective      To investigate the reliability and efficiency of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in the treatment of chronic lymphocytic leukemia (CLL) in young patients.       Methods      The clinical features

laboratory manifestations

transplantation options and prognosis of 3 young male patients (35 to 44 years old) who received HLA-matched allogeneic hematopoietic stem cell transplantation in our department during October 2010 to June 2011 were collected and analyzed. The related literature was also reviewed.       Results      The 3 patients were all younger than 50 years old

and belonged to high risk group in Rai stage. The mean time of leukocytes engraftment was 12 d (ranging from 11 to 13 d)

and the mean time of platelets engraftment was 13 d (ranging from 12 to 14 d). Chronic localized graft-versus-host disease (cGVHD) of the skin was found in 1 patient. Three patients were followed up till April 2012 (mean 25 months). All of three patients had a disease-free-survival.       Conclusion      Allo-HSCT is the only method having a possibility to cure CLL. We suggest that Allo-HSCT should be used for young high-risk CLL patients with suitable donors.